• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
An outbreak of RSV infections in a neonatology clinic during the RSV-season.在 RSV 季节,新生儿科诊所爆发 RSV 感染。
BMC Pediatr. 2021 Dec 11;21(1):567. doi: 10.1186/s12887-021-03053-9.
2
Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials.尼塞利珠单抗预防早产儿和足月儿呼吸道合胞病毒下呼吸道感染的疗效,以及对伴有先天性心脏病和慢性肺部疾病的婴儿的药代动力学外推:一项随机对照试验的汇总分析。
Lancet Child Adolesc Health. 2023 Mar;7(3):180-189. doi: 10.1016/S2352-4642(22)00321-2. Epub 2023 Jan 9.
3
Respiratory syncytial virus hospitalizations in infants of 28 weeks gestational age and less in the palivizumab era.在帕利珠单抗时代,胎龄28周及以下婴儿因呼吸道合胞病毒住院的情况。
Int J Infect Dis. 2017 Apr;57:50-53. doi: 10.1016/j.ijid.2017.01.034. Epub 2017 Feb 2.
4
Impact of the Withdrawal of Palivizumab Immunoprophylaxis on the Incidence of Respiratory Syncytial Virus (RSV) Hospitalizations Among Infants Born at 33 to 35 Weeks' Gestational Age in the Province of Quebec, Canada: The RSV-Quebec Study.加拿大魁北克省 33 至 35 孕周出生婴儿中帕利珠单抗免疫预防的撤用对呼吸道合胞病毒(RSV)住院发生率的影响:RSV-魁北克研究。
J Pediatric Infect Dis Soc. 2021 Apr 3;10(3):237-244. doi: 10.1093/jpids/piaa046.
5
Respiratory syncytial virus prophylaxis in preterm infants: a cost-effectiveness study from Turkey.土耳其早产婴儿呼吸道合胞病毒预防:一项成本效益研究
Turk J Pediatr. 2012 Jul-Aug;54(4):344-51.
6
Infant respiratory syncytial virus prophylaxis and nasopharyngeal microbiota until 6 years of life: a subanalysis of the MAKI randomised controlled trial.婴儿呼吸道合胞病毒预防和鼻咽微生物群直到 6 岁:MAKI 随机对照试验的亚分析。
Lancet Respir Med. 2020 Oct;8(10):1022-1031. doi: 10.1016/S2213-2600(19)30470-9. Epub 2020 Mar 20.
7
Risk factors for hospitalisation due to respiratory syncytial virus infection in children receiving prophylactic palivizumab.接受预防性帕利珠单抗治疗的儿童因呼吸道合胞病毒感染而住院的风险因素。
Eur J Pediatr. 2022 Feb;181(2):539-547. doi: 10.1007/s00431-021-04216-7. Epub 2021 Aug 21.
8
Predictors and incidence of hospitalization due to respiratory syncytial virus (RSV)-associated lower respiratory tract infection (LRTI) in non-prophylaxed moderate-to-late preterm infants in Bosnia and Herzegovina.在波斯尼亚和黑塞哥维那,未进行预防接种的中度至晚期早产儿因呼吸道合胞病毒(RSV)相关下呼吸道感染(LRTI)而住院的预测因素和发生率。
Bosn J Basic Med Sci. 2018 Aug 1;18(3):279-288. doi: 10.17305/bjbms.2018.2318.
9
Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.帕利珠单抗是一种人源化呼吸道合胞病毒单克隆抗体,可降低高危婴儿因呼吸道合胞病毒感染而住院的几率。IMpact-RSV研究小组。
Pediatrics. 1998 Sep;102(3 Pt 1):531-7.
10
Cost-utility analysis of palivizumab for preventing respiratory syncytial virus in preterm neonates and infants in Colombia.哥伦比亚早产儿和婴儿使用帕利珠单抗预防呼吸道合胞病毒的成本-效用分析。
BMC Infect Dis. 2024 Apr 19;24(1):418. doi: 10.1186/s12879-024-09300-5.

引用本文的文献

1
Global outbreaks of respiratory syncytial virus infections from 1960 to 2025: a systematic review and meta-analysis.1960年至2025年呼吸道合胞病毒感染的全球暴发:一项系统评价和荟萃分析
EClinicalMedicine. 2025 Jul 10;86:103352. doi: 10.1016/j.eclinm.2025.103352. eCollection 2025 Aug.
2
Effectiveness of nirsevimab immunization against RSV infection in preterm infants: a systematic review and meta-analysis.尼塞韦单抗免疫接种对早产儿呼吸道合胞病毒感染的有效性:一项系统评价和荟萃分析
Front Immunol. 2025 Apr 17;16:1581970. doi: 10.3389/fimmu.2025.1581970. eCollection 2025.
3
SHEA practice update: infection prevention and control (IPC) in residential facilities for pediatric patients and their families.医疗保健流行病学学会(SHEA)实践更新:儿科患者及其家庭居住设施中的感染预防与控制(IPC)
Infect Control Hosp Epidemiol. 2024 Nov 14;46(1):1-24. doi: 10.1017/ice.2024.124.
4
Structural basis of paramyxo- and pneumovirus polymerase inhibition by non-nucleoside small-molecule antivirals.副黏病毒和肺病毒聚合酶非核苷小分子抗病毒药物抑制的结构基础。
Antimicrob Agents Chemother. 2024 Oct 8;68(10):e0080024. doi: 10.1128/aac.00800-24. Epub 2024 Aug 20.
5
Efficacy and safety of respiratory syncytial virus vaccination during pregnancy to prevent lower respiratory tract illness in newborns and infants: a systematic review and meta-analysis of randomized controlled trials.孕期接种呼吸道合胞病毒疫苗预防新生儿和婴儿下呼吸道疾病的有效性和安全性:一项随机对照试验的系统评价和荟萃分析
Front Pediatr. 2024 Jan 31;11:1260740. doi: 10.3389/fped.2023.1260740. eCollection 2023.
6
Impact of breastfeeding on the incidence and severity of respiratory syncytial virus (RSV)-associated acute lower respiratory infections in infants: a systematic review highlighting the global relevance of primary prevention.母乳喂养对婴儿呼吸道合胞病毒(RSV)相关急性下呼吸道感染的发生率和严重程度的影响:系统评价强调初级预防的全球相关性。
BMJ Glob Health. 2023 Feb;8(2). doi: 10.1136/bmjgh-2022-009693.
7
Immune escaping of the novel genotypes of human respiratory syncytial virus based on gene sequence variation.基于基因序列变异的新型人呼吸道合胞病毒的免疫逃逸。
Front Immunol. 2023 Jan 10;13:1084139. doi: 10.3389/fimmu.2022.1084139. eCollection 2022.
8
A delayed resurgence of respiratory syncytial virus (RSV) during the COVID-19 pandemic: An unpredictable outbreak in a small proportion of children in the Southwest of Iran, April 2022.2022 年 4 月,伊朗西南部一小部分儿童出现了 COVID-19 大流行期间呼吸道合胞病毒(RSV)的延迟反弹:一次不可预测的暴发。
J Med Virol. 2022 Dec;94(12):5802-5807. doi: 10.1002/jmv.28065. Epub 2022 Aug 23.

本文引用的文献

1
Nosocomial Respiratory Viral Infection in the Neonatal Intensive Care Unit.新生儿重症监护病房的医院获得性呼吸道病毒感染。
Am J Perinatol. 2020 Sep;37(S 02):S22-S25. doi: 10.1055/s-0040-1714081. Epub 2020 Sep 8.
2
Viral pathogens associated with acute lower respiratory tract infections in children younger than 5 years of age in Bulgaria.保加利亚5岁以下儿童急性下呼吸道感染相关的病毒病原体
Braz J Microbiol. 2019 Jan;50(1):117-125. doi: 10.1007/s42770-018-0033-2. Epub 2018 Dec 5.
3
Should we use Palivizumab immunoprophylaxis for infants against respiratory syncytial virus? - a cost-utility analysis.我们应该使用帕利珠单抗对婴儿进行呼吸道合胞病毒免疫预防吗?——一项成本效用分析。
Isr J Health Policy Res. 2018 Dec 17;7(1):63. doi: 10.1186/s13584-018-0258-4.
4
Population-based trends and underlying risk factors for infant respiratory syncytial virus and bronchiolitis hospitalizations.基于人群的婴儿呼吸道合胞病毒和细支气管炎住院的趋势及潜在危险因素。
PLoS One. 2018 Oct 31;13(10):e0205399. doi: 10.1371/journal.pone.0205399. eCollection 2018.
5
Neonatal outcomes following new reimbursement limitations on palivizumab in Italy.意大利新的帕利珠单抗报销限制对新生儿结局的影响。
Arch Dis Child. 2018 Dec;103(12):1163-1167. doi: 10.1136/archdischild-2018-315349. Epub 2018 Sep 14.
6
Risk scoring tool to predict respiratory syncytial virus hospitalisation in premature infants.预测早产儿呼吸道合胞病毒住院风险的评分工具。
Pediatr Pulmonol. 2018 May;53(5):605-612. doi: 10.1002/ppul.23960. Epub 2018 Feb 6.
7
Palivizumab administration in preterm infants in France: EPIPAGE-2 cohort study.法国早产儿中帕利珠单抗的应用:EPIPAGE-2队列研究
Arch Pediatr. 2018 Feb;25(2):89-94. doi: 10.1016/j.arcped.2017.12.009. Epub 2018 Feb 1.
8
Respiratory syncytial virus vaccine research and development: World Health Organization technological roadmap and preferred product characteristics.呼吸道合胞病毒疫苗的研发:世界卫生组织技术路线图和优先产品特征。
Vaccine. 2019 Nov 28;37(50):7394-7395. doi: 10.1016/j.vaccine.2017.09.092. Epub 2018 Feb 1.
9
Prevalence and genetic characterisation of respiratory syncytial viruses circulating in Bulgaria during the 2014/15 and 2015/16 winter seasons.2014/15 年和 2015/16 年冬季保加利亚流行的呼吸道合胞病毒的流行情况和遗传特征。
Pathog Glob Health. 2017 Oct;111(7):351-361. doi: 10.1080/20477724.2017.1375708. Epub 2017 Sep 26.
10
Effectiveness of Palivizumab in High-risk Infants and Children: A Propensity Score Weighted Regression Analysis.帕利珠单抗在高危婴幼儿中的有效性:倾向评分加权回归分析
Pediatr Infect Dis J. 2017 Aug;36(8):699-704. doi: 10.1097/INF.0000000000001533.

在 RSV 季节,新生儿科诊所爆发 RSV 感染。

An outbreak of RSV infections in a neonatology clinic during the RSV-season.

机构信息

Department of Obstetrics and Gynecology, Medical University of Sofia, Zdrave 2 street, 1431, Sofia, Bulgaria.

Neonatology Clinic, University Hospital of Obstetrics and Gynecology "Maichin Dom", Sofia, Bulgaria.

出版信息

BMC Pediatr. 2021 Dec 11;21(1):567. doi: 10.1186/s12887-021-03053-9.

DOI:10.1186/s12887-021-03053-9
PMID:34895173
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8665584/
Abstract

BACKGROUND

Respiratory syncytial virus (RSV) is the predominant cause of lower respiratory tract infections (LRTI) in infancy. Preterm infants with bronchopulmonary dysplasia (BPD) are at the highest risk of severe RSV-LRTI. This is a retrospective study that analyses a nosocomial outbreak of RSV infections in the Neonatology clinic of the University Hospital of Obstetrics and Gynecology, Sofia, 2019.

METHODS

Two groups of infants without contact between them were diagnosed with RSV-infection: 14 infants were treated in the Department for healthy newborns - Group 1, and 7 preterm infants were treated in the Neonatal Intensive Care Unit (NICU) - Group 2. The detection of RSV was performed using Real-Time PCR in nasal/throat swabs.

RESULTS

Respiratory symptoms occurred 2-5 days after discharge in 14 of 148 healthy term infants born February 5 to 18, 2019; 12 babies were re-hospitalized with LRTI and recovered in a few days. RSV-PCR was positive in 6 infants, while in the others, RSV etiology was suggested, due to similar symptoms and contact between them. The first NICU patient with RSV-LRTI was one of the 26 gestational weeks (GW) twins, who had severe BPD. The other twin was always discharged home without LRTI-symptoms. In the period February 19 to March 15, 2019, 26 premature babies born at 26-34 GW, were tested for RSV (33 nasal/throat swabs). They received a first or subsequent palivizumab injection. We identified 11 positive samples in 7 of the babies. Despite the clinical recovery, the second RSV-PCR remained positive in 4 babies. Six of the 7 NICU patients had symptoms of LRTI, and two of them needed mechanical ventilation. Six babies were discharged home after stabilization, one was transferred to the Pediatric department for further treatment of BPD and later discharged too.

CONCLUSIONS

This was the most serious outbreak of RSV infections in neonates since the RSV-PCR diagnostic in Bulgaria was introduced. The course of RSV-LRTI was severe in extremely preterm patients with underlying BPD. So, routine in-hospital RSV-prophylaxis with palivizumab should be considered for infants at the highest risk.

摘要

背景

呼吸道合胞病毒(RSV)是婴儿下呼吸道感染(LRTI)的主要原因。患有支气管肺发育不良(BPD)的早产儿患严重 RSV-LRTI 的风险最高。这是一项回顾性研究,分析了 2019 年索非亚妇产医院新生儿科的 RSV 感染医院内暴发情况。

方法

两组婴儿无接触,均被诊断为 RSV 感染:14 名婴儿在新生儿科治疗-第 1 组,7 名早产儿在新生儿重症监护病房(NICU)治疗-第 2 组。使用实时 PCR 在鼻/咽拭子中检测 RSV。

结果

2019 年 2 月 5 日至 18 日出生的 148 名健康足月婴儿中,有 14 名在出院后 2-5 天出现呼吸道症状;12 名婴儿因 LRTI 再次住院,数天内康复。6 名婴儿的 RSV-PCR 阳性,而其他婴儿由于类似症状和接触,提示 RSV 病因。第一个患 RSV-LRTI 的 NICU 患者是 26 孕周(GW)双胞胎之一,患有严重的 BPD。另一个双胞胎始终无 LRTI 症状出院。在 2019 年 2 月 19 日至 3 月 15 日期间,对 26-34 GW 出生的 26 名早产儿进行了 RSV 检测(33 份鼻/咽拭子)。他们接受了第一或后续的帕利珠单抗注射。在 7 名婴儿中发现了 11 个阳性样本。尽管临床康复,但 4 名婴儿的第二次 RSV-PCR 仍为阳性。7 名 NICU 患者中有 6 名出现 LRTI 症状,其中 2 名需要机械通气。6 名婴儿稳定后出院,1 名因 BPD 转至儿科进一步治疗,后也出院。

结论

这是保加利亚引入 RSV-PCR 诊断以来新生儿中最严重的 RSV 感染暴发。患有潜在 BPD 的极早产儿的 RSV-LRTI 病程严重。因此,应考虑对高危婴儿进行常规住院 RSV 预防用帕利珠单抗治疗。